Genetic 'placebo response' marker has trial design implications, say researchers

- Last updated on GMT

Team discovers genetic basis for placebo response
Discovery of the genetic basis for the placebo effect in IBS patients has wider implications for protocol design and trials of personalised medicines say researchers.

Scientists from Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) claim to have identified​ genetic differences between people who respond to placebos during trials of and those who do not.

The team looked a 2003 trial (NCT00065403​) in which patients ‘treated’ with augmented placebo – combined acupuncture and physician support – showed greater reductions in symptom severity than patients in either the limited placebo group – just acupuncture – or the no treatment arm.

Analysis of blood samples taken at the time showed patients who responded most strongly had two copies of a particular version of a gene encoding catechol-O-methyltransferase (COMT), an enzyme involved in the dopamine pathway, as lead author Kathryn Hall explained.

IBS patients homozygous for the COMT val158met methionine allele were the most responsive to placebo treatment. Heterozygous patients showed an intermediate response, and homozygous valine patients showed essentially no placebo mediated symptom improvement​.”

And while the researchers admit the study was only small scale – 262 adults took part and only 122 allowed blood samples to be taken – they suggest the genetic findings have wider implications for drug research.

To our knowledge, this is the first study to demonstrate genetic modulation of true placebo effects disassociated from changes related to disease natural history and regression to the mean.

Identifying biological characteristics of placebo responders and non-responders could be key to managing underlying placebogenic factors to benefit patients by delivering personalized medicine, for example by adjusting the dose of medication in accordance to the subject's placebo susceptibility or selecting a different class of drugs for the individualized patient​.”

Related topics: Clinical Development, Phase III-IV

Related news

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers